Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalfurafine for CKD-aP in Hemodialysis Patients
NCT07769073Phase 4Not yet recruiting
- Sponsor
- Universitas Indonesia
- Start
- Aug 2026
- Primary completion
- Sep 2026
01
Overview
Phase 4, randomised trial of nalfurafine in chronic kidney disease (CKD) (2 arms), sponsored by Universitas Indonesia. Primary endpoint: Visual Analog Scale for pruritus at 4 weeks. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
nalfurafine
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07769073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07769073.